A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

NCT01966471 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1846

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab Emtansine
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Doxorubicin
DRUG: Docetaxel
DRUG: Cyclophosphamide
DRUG: 5-Fluorouracil

Sponsor

Hoffmann-La Roche